Comparative Study of Snedds and Sedds for Enhancing Oral Delivery of Vildagliptin

Dipeptidyl peptidase-4 (DPP-4) inhibitors vildagliptin, which is broadly used in the treatment of type 2 diabetes mellitus, not only lacks high aqueous solubility, but also has a low variable oral bioavailability, which creates great difficulties in drug delivery. Self-Emulsifying Drug Delivery Systems (SEDDS) and Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) have been found to be a potential alternative to these shortcomings based on lipid-formulations. The present study offers a complete comparative study of SNEDDS and SEDDS systems in the enhancement of oral administration of vildagliptin. SNEDDS are more superior to conventional SEDDS in terms of surface area they loop over and also have the advantage of superior absorption of drugs as they form small nano-sized droplets in the event that an aqueous dilution occurs (<100 nm). Oils and surfactants and co-surfactants are the key components of the formulation that are optimized to enable the formulation to produce the maximum drug loading, longer stability and effective emulsification. The quality and their performance criteria were determined by droplet size and polydispersity index (PDI) analysis, zeta potential measurement, in vitro dissolution analysis, testing thermodynamic stability as well as morphological/spectroscopic assessment of the formulations. SNEDDS had improved physicochemical stability, dissolution rates, and drug releasing patterns in consistent relation to SEDDS. Nevertheless, issues bearing on drug precipitation on dilution, formulation stability, scalability and mass-manufacturing, economics and regulatory consistency are the greatest problems in commercial-scale application. With these problems still in play, however, significant progress in solid-SNEDDS technologies, excipient innovation, and harmonization of regulatory toolkits are slowly facilitating the transformation of these systems, in the development stage, to commercial products. The research finding is that SNEDDS can provide a superior and solid solution to enhance the oral delivery of vildagliptin with high prospect of clinical practice and commercial use. This study supports the significance of lipid-based nanoformulations in the current pharmaceutical formulations and their use in overcoming the solubility and bioavailability challenges of important therapeutic methods.